Cargando…

Mechanisms Underlying the Inhibition of Tyrosine Kinase Inhibitor-Induced Anorexia and Fatigue by Royal Jelly in Renal Cell Carcinoma Patients and the Correlation between Macrophage Colony Stimulating Factor and Inflammatory Mediators

Inflammation is a common adverse event of anti-cancer therapy. Royal jelly (RJ) modulates inflammation by regulating the levels of tumor necrosis factor (TNF)-α, transforming growth factor (TGF)-β, and interleukin (IL)-6 produced by macrophages. Macrophage colony stimulating factor (M-CSF) is a cruc...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuno, Tsutomu, Miyata, Yasuyoshi, Mukae, Yuta, Otsubo, Asato, Mitsunari, Kensuke, Matsuo, Tomohiro, Ohba, Kojiro, Sakai, Hideki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712565/
https://www.ncbi.nlm.nih.gov/pubmed/33050250
http://dx.doi.org/10.3390/medsci8040043
_version_ 1783618400136724480
author Yuno, Tsutomu
Miyata, Yasuyoshi
Mukae, Yuta
Otsubo, Asato
Mitsunari, Kensuke
Matsuo, Tomohiro
Ohba, Kojiro
Sakai, Hideki
author_facet Yuno, Tsutomu
Miyata, Yasuyoshi
Mukae, Yuta
Otsubo, Asato
Mitsunari, Kensuke
Matsuo, Tomohiro
Ohba, Kojiro
Sakai, Hideki
author_sort Yuno, Tsutomu
collection PubMed
description Inflammation is a common adverse event of anti-cancer therapy. Royal jelly (RJ) modulates inflammation by regulating the levels of tumor necrosis factor (TNF)-α, transforming growth factor (TGF)-β, and interleukin (IL)-6 produced by macrophages. Macrophage colony stimulating factor (M-CSF) is a crucial regulator of macrophage activities, and we hypothesized that RJ alters M-CSF levels. In this randomized controlled trial, we investigated the association between M-CSF and adverse events in renal cell carcinoma patients treated with tyrosine kinase inhibitors (TKIs) after an oral intake of RJ (n = 16) or placebo (n = 17). The serum levels of M-CSF, TNF-α, TGF-β, and IL-6 were measured by an enzyme-linked immunosorbent assay, and their temporal changes and correlation between such changes were analyzed. The post-/pretreatment ratio of M-CSF levels was associated with anorexia after 2 weeks and fatigue after 2, 4, and 12 weeks. The M-CSF level in the RJ group was higher than that in the placebo group at the same timepoints. The TNF-α level in the RJ group was lower than that in the placebo group between 6 and 12 weeks, and the TGF-β level in the RJ group was higher than that in the placebo group; however, contrasting findings were detected after 12 weeks. Additionally, the M-CSF level was significantly correlated with the TGF-β level after 4 weeks and IL-6 level after 8 and 10 weeks. Among TNF-α, TGF-β, and IL-6, the post-/pretreatment ratio of TGF-β after 12 weeks was associated with TKI-induced anorexia, and the ratios after 10 and 12 weeks were associated with fatigue. Our results demonstrated that an oral intake of RJ suppressed anorexia and fatigue via complex mechanisms associated with inflammation-related factors, such as M-CSF and TGF-β in renal cell carcinoma patients treated with TKIs. In addition, we newly found that such RJ-related effects were dependent on the treatment duration.
format Online
Article
Text
id pubmed-7712565
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77125652020-12-04 Mechanisms Underlying the Inhibition of Tyrosine Kinase Inhibitor-Induced Anorexia and Fatigue by Royal Jelly in Renal Cell Carcinoma Patients and the Correlation between Macrophage Colony Stimulating Factor and Inflammatory Mediators Yuno, Tsutomu Miyata, Yasuyoshi Mukae, Yuta Otsubo, Asato Mitsunari, Kensuke Matsuo, Tomohiro Ohba, Kojiro Sakai, Hideki Med Sci (Basel) Article Inflammation is a common adverse event of anti-cancer therapy. Royal jelly (RJ) modulates inflammation by regulating the levels of tumor necrosis factor (TNF)-α, transforming growth factor (TGF)-β, and interleukin (IL)-6 produced by macrophages. Macrophage colony stimulating factor (M-CSF) is a crucial regulator of macrophage activities, and we hypothesized that RJ alters M-CSF levels. In this randomized controlled trial, we investigated the association between M-CSF and adverse events in renal cell carcinoma patients treated with tyrosine kinase inhibitors (TKIs) after an oral intake of RJ (n = 16) or placebo (n = 17). The serum levels of M-CSF, TNF-α, TGF-β, and IL-6 were measured by an enzyme-linked immunosorbent assay, and their temporal changes and correlation between such changes were analyzed. The post-/pretreatment ratio of M-CSF levels was associated with anorexia after 2 weeks and fatigue after 2, 4, and 12 weeks. The M-CSF level in the RJ group was higher than that in the placebo group at the same timepoints. The TNF-α level in the RJ group was lower than that in the placebo group between 6 and 12 weeks, and the TGF-β level in the RJ group was higher than that in the placebo group; however, contrasting findings were detected after 12 weeks. Additionally, the M-CSF level was significantly correlated with the TGF-β level after 4 weeks and IL-6 level after 8 and 10 weeks. Among TNF-α, TGF-β, and IL-6, the post-/pretreatment ratio of TGF-β after 12 weeks was associated with TKI-induced anorexia, and the ratios after 10 and 12 weeks were associated with fatigue. Our results demonstrated that an oral intake of RJ suppressed anorexia and fatigue via complex mechanisms associated with inflammation-related factors, such as M-CSF and TGF-β in renal cell carcinoma patients treated with TKIs. In addition, we newly found that such RJ-related effects were dependent on the treatment duration. MDPI 2020-10-09 /pmc/articles/PMC7712565/ /pubmed/33050250 http://dx.doi.org/10.3390/medsci8040043 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yuno, Tsutomu
Miyata, Yasuyoshi
Mukae, Yuta
Otsubo, Asato
Mitsunari, Kensuke
Matsuo, Tomohiro
Ohba, Kojiro
Sakai, Hideki
Mechanisms Underlying the Inhibition of Tyrosine Kinase Inhibitor-Induced Anorexia and Fatigue by Royal Jelly in Renal Cell Carcinoma Patients and the Correlation between Macrophage Colony Stimulating Factor and Inflammatory Mediators
title Mechanisms Underlying the Inhibition of Tyrosine Kinase Inhibitor-Induced Anorexia and Fatigue by Royal Jelly in Renal Cell Carcinoma Patients and the Correlation between Macrophage Colony Stimulating Factor and Inflammatory Mediators
title_full Mechanisms Underlying the Inhibition of Tyrosine Kinase Inhibitor-Induced Anorexia and Fatigue by Royal Jelly in Renal Cell Carcinoma Patients and the Correlation between Macrophage Colony Stimulating Factor and Inflammatory Mediators
title_fullStr Mechanisms Underlying the Inhibition of Tyrosine Kinase Inhibitor-Induced Anorexia and Fatigue by Royal Jelly in Renal Cell Carcinoma Patients and the Correlation between Macrophage Colony Stimulating Factor and Inflammatory Mediators
title_full_unstemmed Mechanisms Underlying the Inhibition of Tyrosine Kinase Inhibitor-Induced Anorexia and Fatigue by Royal Jelly in Renal Cell Carcinoma Patients and the Correlation between Macrophage Colony Stimulating Factor and Inflammatory Mediators
title_short Mechanisms Underlying the Inhibition of Tyrosine Kinase Inhibitor-Induced Anorexia and Fatigue by Royal Jelly in Renal Cell Carcinoma Patients and the Correlation between Macrophage Colony Stimulating Factor and Inflammatory Mediators
title_sort mechanisms underlying the inhibition of tyrosine kinase inhibitor-induced anorexia and fatigue by royal jelly in renal cell carcinoma patients and the correlation between macrophage colony stimulating factor and inflammatory mediators
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712565/
https://www.ncbi.nlm.nih.gov/pubmed/33050250
http://dx.doi.org/10.3390/medsci8040043
work_keys_str_mv AT yunotsutomu mechanismsunderlyingtheinhibitionoftyrosinekinaseinhibitorinducedanorexiaandfatiguebyroyaljellyinrenalcellcarcinomapatientsandthecorrelationbetweenmacrophagecolonystimulatingfactorandinflammatorymediators
AT miyatayasuyoshi mechanismsunderlyingtheinhibitionoftyrosinekinaseinhibitorinducedanorexiaandfatiguebyroyaljellyinrenalcellcarcinomapatientsandthecorrelationbetweenmacrophagecolonystimulatingfactorandinflammatorymediators
AT mukaeyuta mechanismsunderlyingtheinhibitionoftyrosinekinaseinhibitorinducedanorexiaandfatiguebyroyaljellyinrenalcellcarcinomapatientsandthecorrelationbetweenmacrophagecolonystimulatingfactorandinflammatorymediators
AT otsuboasato mechanismsunderlyingtheinhibitionoftyrosinekinaseinhibitorinducedanorexiaandfatiguebyroyaljellyinrenalcellcarcinomapatientsandthecorrelationbetweenmacrophagecolonystimulatingfactorandinflammatorymediators
AT mitsunarikensuke mechanismsunderlyingtheinhibitionoftyrosinekinaseinhibitorinducedanorexiaandfatiguebyroyaljellyinrenalcellcarcinomapatientsandthecorrelationbetweenmacrophagecolonystimulatingfactorandinflammatorymediators
AT matsuotomohiro mechanismsunderlyingtheinhibitionoftyrosinekinaseinhibitorinducedanorexiaandfatiguebyroyaljellyinrenalcellcarcinomapatientsandthecorrelationbetweenmacrophagecolonystimulatingfactorandinflammatorymediators
AT ohbakojiro mechanismsunderlyingtheinhibitionoftyrosinekinaseinhibitorinducedanorexiaandfatiguebyroyaljellyinrenalcellcarcinomapatientsandthecorrelationbetweenmacrophagecolonystimulatingfactorandinflammatorymediators
AT sakaihideki mechanismsunderlyingtheinhibitionoftyrosinekinaseinhibitorinducedanorexiaandfatiguebyroyaljellyinrenalcellcarcinomapatientsandthecorrelationbetweenmacrophagecolonystimulatingfactorandinflammatorymediators